Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FTY720 in chronic hepatitis C patients intolerant or non-responsive to interferon
2004-000664-27Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fingolimod in hepatitis C virus infection, sponsored by Novartis. Primary endpoint: Change in serum hepatitis C viral load. Started May 2005; status: completed.
02
Drugs
fingolimod
03
Conditions
hepatitis C virus infection
Beyond the preview
Go deeper on 2004-000664-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-000664-27.